María Santos-Galindo

María Santos-Galindo

Auto-generated profile, based on publicly available information

María Santos-Galindo

Instituto Cajal, C.S.I.C., Madrid, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2014 in Nature Medicine
Verified
Journal Article
Closed access
MFMarta Fernández-Nogales
Marta Fernández-Nogales
JCJorge R Cabrera
Jorge R Cabrera
MSMaría Santos-Galindo
María Santos-Galindo
JHJeroen J M Hoozemans
Jeroen J M Hoozemans
IFIsidro Ferrer
Isidro Ferrer
JLJosé J Lucas
José J Lucas

1 October 2010 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
M.-A. ArevaloM.-A. Arevalo
M.-A. Arevalo
MSMaría Santos-Galindo
María Santos-Galindo
MBMaria Jose Bellini
Maria Jose Bellini
IAIñigo Azcoitia
Iñigo Azcoitia
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura

11 July 2011 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
MSMaría Santos-Galindo
María Santos-Galindo
EAEstefanía Acaz-Fonseca
Estefanía Acaz-Fonseca
MBMaria Jose Bellini
Maria Jose Bellini
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura
Background: Numerous neurological and psychiatric disorders show sex differences in incidence, age of onset, symptomatology or outcome. Astrocytes, one of the glial cell types of the brain, show sex differences in number, differentiation and function. Since astrocytes are involved in the response of neural tissue to injury and inflammation, these cells may participate in the generation of sex differences in the response of the brain to pathological insults. To explore this hypothesis, we have examined whether male and female astrocytes show a different response to an inflammatory challenge and whether perinatal testosterone influences this response.Methods: Cortical astrocyte cultures were prepared from postnatal day 1 (one day after birth) male or female CD1 mice pups. In addition, cortical astrocyte cultures were also prepared from female pups that were injected at birth with 100 μg of testosterone propionate or vehicle. Cultures were treated for 5 hours with medium containing lipopolysaccharide (LPS) or with control medium. The mRNA levels of IL6, interferon-inducible protein 10 (IP10), TNFα, IL1β, Toll-like receptor 4 (TLR4), steroidogenic acute regulatory protein and translocator protein were assessed by quantitative real-time polymerase chain reaction. Statistical significance was assessed by unpairedt-test or by one-way analysis of variance followed by the Tukeypost hoctest.Results: The mRNA levels of IL6, TNFα and IL1β after LPS treatment were significantly higher in astrocytes derived from male or androgenized females compared to astrocytes derived from control or vehicle-injected females. In contrast, IP10 mRNA levels after LPS treatment were higher in astrocytes derived from control or vehicle-injected females than in those obtained from males or androgenized females. The different response of male and female astrocytes to LPS was due neither to differences in the basal expression of the inflammatory molecules nor to differences in the expression of the LPS receptor TLR4. In contrast, the different inflammatory response was associated with increased mRNA levels of translocator protein, a key steroidogenic regulator, in female astrocytes that were treated with LPS.Conclusions: Male and female cortical astrocytes respond differentially to an inflammatory challenge and this may be predetermined by perinatal testosterone exposure.

11 November 2010 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
M.-A. ArevaloM.-A. Arevalo
M.-A. Arevalo
MSMaría Santos-Galindo
María Santos-Galindo
NLNatalia Lagunas
Natalia Lagunas
IAIñigo Azcoitia
Iñigo Azcoitia
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura
Selective estrogen receptor modulators (SERMs), used for the treatment of breast cancer, osteoporosis, and menopausal symptoms, affect the nervous system. Some SERMs trigger neuroprotective mechanisms and reduce neural damage in different experimental models of neural trauma, brain inflammation, neurodegenerative diseases, cognitive impairment, and affective disorders. New SERMs with specific actions on neurons and glial cells may represent promising therapeutic tools for the brain.

24 September 2009 in Endocrinology
Verified
Journal Article
Closed access
GBGeorge E. Barreto
George E. Barreto
MSMaría Santos-Galindo
María Santos-Galindo
YDYolanda Diz-Chaves
Yolanda Diz-Chaves
OPOlga Pernía
Olga Pernía
PCPaloma Carrero
Paloma Carrero
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura
After brain injury, astrocytes acquire a reactive phenotype characterized by a series of morphological and molecular modifications, including the expression of the cytoskeletal protein vimentin. Previous studies have shown that estradiol down-regulates reactive astrogliosis. In this study we assessed whether raloxifene and tamoxifen, two selective estrogen receptor modulators, have effects similar to estradiol in astrocytes. We also assessed whether aging and the timing of estrogenic therapy after ovariectomy influence the action of the estrogenic compounds. Four groups of animals were studied: 1) young rats, ovariectomized at 2 months of age; 2) middle-aged rats, ovariectomized at 8 months of age; 3) aged rats, ovariectomized at 18 months of age; and 4) aged rats, ovariectomized at 2 months and sham operated at 18 months of age. Fifteen days after ovariectomy or sham surgery, animals received a stab wound brain injury and the treatment with the estrogenic compounds. The number of vimentin-immunoreactive astrocytes after injury was significantly higher in the hippocampus of aged rats after a long-term ovariectomy compared with aged animals after a short-term ovariectomy and middle-aged rats. In addition, reactive astrocytes were more numerous in the two groups of aged animals than in young animals. Despite these differences, the estrogenic compounds reduced reactive astrogliosis in all animal groups. These findings indicate that estradiol, raloxifene, and tamoxifen are potential candidates for the control of astrogliosis in young and older individuals and after a prolonged depletion of ovarian hormones.

20 December 2011 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
M.-A. ArevaloM.-A. Arevalo
M.-A. Arevalo
YDYolanda Diz-Chaves
Yolanda Diz-Chaves
MSM. Santos‐Galindo
M. Santos‐Galindo
MBMaria Jose Bellini
Maria Jose Bellini
LGLuis Miguel Garcia-Segura
Luis Miguel Garcia-Segura